Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and Famitinib Maintenance in Advanced Ovarian Cancer
NCT07382713Phase 2Not yet recruiting
- Sponsor
- Jinhua Zhou
- Start
- Feb 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and famitinib in ovarian cancer, sponsored by Jinhua Zhou. Primary endpoint: Progression-Free Survival at 48 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
fluzoparibfamitinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07382713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07382713.